In this episode, you'll be listening to Jane Hughes, President of R&amp;D and Co Founder of Verdiva Bio, and Jon Rees, CEO and cofounder of MitoRx Therapeutics. We'll discuss next-generation obesity solutions tackling GLP-1's muscle loss and adherence challenges, through innovative muscle preservation, oral administration and combination therapy. Host<a href="https://www.linkedin.com/in/jennifersmithparker/" rel="noopener noreferrer nofollow">Jennifer Smith-Parker</a>, Director of Insights, BioSpace Guests<a href="https://www.linkedin.com/in/jane-hughes-856ba48/" rel="noopener noreferrer nofollow">Jane Hughes</a>, President of R&amp;D and Co-founder, Verdiva Bio<a href="https://www.linkedin.com/in/jondrees/?originalSubdomain=uk" rel="noopener noreferrer nofollow">Jon Rees</a>, CEO and Co-founder, MitoRx Therapeutics Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Corsera Eyes Two-Pronged Approach To Tackle Leading Cardiovascular Killer

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.